BIO International Convention 2020 – BIO Digital, virtual

SynDermix attends virtual BIO International Convention 2020 – BIO Digital



SynDermix AG announced today that the Company is participating in BIO Digital 2020 with a Company Presentation and its BIO One-on-One Partnering™ held virtually between 8 and 12 June 2020. Organised by the Biotechnology Industry Organization (BIO), the five-day event will convene via an online platform, in alignment with international health recommendations against the spread of COVID-19. The event will focus on collaboration and partnership, with expert-level educational content from Key Opinion Leaders in the biotech and MedTech industries, and both live and on-demand sessions. It also features BIO One-on-One Partnering™, a networking system for attendees to identify and schedule virtual meetings with potential partners.

SynDermix is represented at BIO Digital 2020, by the Company’s Designated Managing Director, Dr Konstantinos Efthymiopoulos. Dr Efthymiopoulos stated: “The main goal of SynDermix at BIO Digital this year will be to touch base with industry partners who have an interest in discussing our ENT medical device and most advanced asset, SDX-3101. I am pleased to say we already have meetings planned with a number of potential partners from different parts of the world.”

About SynDermix AG

SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.

SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit:



Julian Heinrich